Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge of 9.45% on Thursday, as the telehealth company announced a major expansion of its weight loss portfolio.

The stock movement follows the company's announcement that it will begin offering compounded copies of Novo Nordisk's Wegovy weight-loss pill at an introductory price of $49 per month. This represents a substantial discount compared to the approximately $199 charged by Novo Nordisk for the branded version. Following an initial payment, patients with a five-month subscription will pay $99 per month thereafter.

The compounded product uses the same active ingredient, semaglutide, as Novo's Wegovy but employs a different formulation and delivery system than FDA-approved oral semaglutide. Hims & Hers has doubled its facility footprint in 2025, which the company says enables it to provide treatments at more accessible price points, creating new competitive dynamics in the lucrative weight-loss drug market.